CGNL1 inhibitors belong to a specific category of chemical compounds designed to target and inhibit the activity of the CGNL1 protein, also known as cingulin-like 1. CGNL1 is a member of the cingulin family of proteins, which are primarily associated with the organization and maintenance of tight junctions in epithelial and endothelial cells. Tight junctions are specialized cell-cell junctions that play a crucial role in regulating the paracellular permeability of epithelial and endothelial barriers. They are essential for maintaining the integrity of these barriers, ensuring selective passage of ions, molecules, and solutes between adjacent cells, and establishing tissue-specific barriers in various organs, such as the gastrointestinal tract and blood-brain barrier. CGNL1, in particular, is involved in the organization of tight junction proteins and the regulation of their functions, contributing to the maintenance of barrier integrity. Inhibitors of CGNL1 are primarily developed for research purposes, serving as vital tools for scientists and researchers to investigate the molecular mechanisms and functions associated with this protein in the context of cell junction biology and cellular physiology.
CGNL1 inhibitors are typically composed of small molecules or chemical compounds specifically designed to interact with the CGNL1 protein, disrupting its normal function in the organization and maintenance of tight junctions. By inhibiting CGNL1, these compounds can potentially interfere with the proper assembly and function of tight junctions, leading to alterations in paracellular permeability and barrier integrity. Researchers use CGNL1 inhibitors in laboratory settings to manipulate the activity of this protein and study its roles in various cellular processes, particularly those related to the formation and regulation of tight junctions. These inhibitors provide valuable insights into the molecular mechanisms by which CGNL1 contributes to the maintenance of epithelial and endothelial barrier function and contribute to a deeper understanding of its significance in the context of cellular physiology and cell junction biology. While CGNL1 inhibitors may have broader implications, their primary purpose is to assist scientists in deciphering the intricacies of CGNL1-mediated tight junction regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Interacts with DNA and inhibits RNA polymerase, which could decrease transcription of genes including CGNL1. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Specifically inhibits RNA polymerase II, potentially lowering the transcription levels of mRNA encoding CGNL1. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
A known autophagy inhibitor that may also impact gene expression and could non-specifically decrease CGNL1 levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Blocks the translocation step in eukaryotic protein synthesis, likely reducing the production of the CGNL1 protein. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $440.00 $900.00 $1400.00 $2502.00 | ||
Inhibits protein synthesis by blocking the ribosomal movement along mRNA, which could reduce CGNL1 protein levels. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
A potential modulator of gene expression that could have an impact on the transcription of the gene encoding CGNL1. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
As a tyrosine kinase inhibitor, it may affect signaling pathways and indirectly modulate CGNL1 expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Binds to GC-rich sequences in DNA, possibly preventing the transcription of certain genes including CGNL1. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Can inhibit mammalian DNA-dependent RNA polymerase, potentially affecting CGNL1 mRNA synthesis. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Inhibits protein synthesis by targeting eukaryotic initiation factors, potentially decreasing CGNL1 expression. | ||||||